Atossa Therapeutics, Inc. (ATOS)
After hours:
| Previous Close | 0.7550 |
| Open | 0.7780 |
| Bid | 0.7400 x 800 |
| Ask | 0.7799 x 1000 |
| Day's Range | 0.7301 - 0.7790 |
| 52 Week Range | 0.5000 - 1.3900 |
| Volume | |
| Avg. Volume | 684,284 |
| Market Cap | 92.641M |
| Beta (5Y Monthly) | 1.28 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.2500 |
| Earnings Date | Nov 06, 2023 - Nov 10, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 4.83 |
Simply Wall St.We're Hopeful That Atossa Therapeutics (NASDAQ:ATOS) Will Use Its Cash Wisely
We can readily understand why investors are attracted to unprofitable companies. For example, although...
ACCESSWIREApproximately 30% Of Newly Diagnosed Cancers In Women Will Be Breast Cancers - Atossa Therapeutics Has A Promising Drug To Help With Prevention And Treatment
One in eight women will be diagnosed with breast cancer during their lifetime. However, breast cancer does not affect all women in the same way, and individual physiology plays a huge factor. Women with dense breast tissue face a higher risk of developing breast cancer and being diagnosed with later-stage disease.
GlobeNewswireAtossa to Present at Cantor Fitzgerald Global Healthcare Conference 2023
SEATTLE, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative proprietary medicines to address significant unmet needs in oncology with a focus on breast cancer, today announces that the Company will take part in the upcoming Cantor Fitzgerald Global Healthcare Conference 2023. Details of the company's participation are as follows: Cantor Fitzgerald Global Healthcare Conference 2023Format: Fireside Chat with
